The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | DEC-C plus venetoclax in HR-MDS and CMML: an analysis using different response criteria
Alex Bataller, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, briefly discusses the findings of an analysis of responses and mutation dynamics in treatment-naïve patients with high-risk myelodysplastic syndrome (HR-MDS) or chronic myelomonocytic leukemia (CMML) treated with a combination of oral decitabine/cedazuridine (DEC-C) and venetoclax (NCT04655755). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
